| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 09/12/2003 | WO2002016591A9 Human transporter family members and uses thereof |
| 09/12/2003 | WO2002010390A9 57250, a human sugar transporter family member and uses thereof |
| 09/12/2003 | WO2001095785A3 Modulation of immune response and methods based thereon |
| 09/12/2003 | WO2001090382A3 Fas ligand-fused proteins |
| 09/12/2003 | WO2001090197A9 Synthetic peptides and uses therefore |
| 09/12/2003 | CA2666005A1 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
| 09/12/2003 | CA2478636A1 Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, and treatments and animal models produced therefrom |
| 09/12/2003 | CA2478298A1 Microarrays of cellulose binding chimeric proteins and methods of use thereof |
| 09/12/2003 | CA2478277A1 Expec-specific proteins, genes encoding them and uses thereof |
| 09/12/2003 | CA2478205A1 Process for producing physiologically active protein using genetically modified silkworm |
| 09/12/2003 | CA2478171A1 Apoptogenic-bacteriocins combining broad spectrum antibiotic and selective anti-tumoral activities, and compositions and uses thereof |
| 09/12/2003 | CA2477969A1 Falp proteins |
| 09/12/2003 | CA2477874A1 Expression cassette for persistence of expression of a gene of interest in muscle cells |
| 09/12/2003 | CA2477856A1 Cold shock inducible expression and production of heterologous polypeptides |
| 09/12/2003 | CA2477836A1 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
| 09/12/2003 | CA2477816A1 Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof |
| 09/12/2003 | CA2477762A1 Peptides for use in antitumor immunotherapy |
| 09/12/2003 | CA2477662A1 Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof |
| 09/12/2003 | CA2477647A1 Dna vaccines encoding cea and a cd40 ligand and methods of use thereof |
| 09/12/2003 | CA2477566A1 Cloning and characterization of slc26a7 and slc26a9 anion exchangers |
| 09/12/2003 | CA2476979A1 Assay for anti-ingap antibodies |
| 09/11/2003 | US20030172411 Disease resistance factors |
| 09/11/2003 | US20030172408 Transcription factor stress-related polypeptides and methods of use in plants |
| 09/11/2003 | US20030172403 Transgenic rice, corn, barley or wheat which express heterologous nucleotide sequences coding proteins and plant regulatory polypeptides such as opaque 2 (O2), prolamin box factor (PBF) and rice endosperm bZIP proteins (REP) in seeds |
| 09/11/2003 | US20030172399 Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids |
| 09/11/2003 | US20030172397 Papaya ringspot virus genes |
| 09/11/2003 | US20030172396 A nucleic acid encoding a transferase enzyme, resistance to a disease caused by Pseudoperonospora or Peronospora; genetic engineering |
| 09/11/2003 | US20030172393 Comprising a modified glucocorticoid receptor, for useing in testing, drug screening, finding drugs treating septic shock, asthma, inflammatory diseases, respiratory system disorders, autoimmune diseases |
| 09/11/2003 | US20030172389 Surfactant protein D for the prevention and diagnosis of pulmonary emphysema |
| 09/11/2003 | US20030172388 Methods and compositions relating to fortilin, an anti-apoptotic molecule, and modulators of fortilin |
| 09/11/2003 | US20030171874 Determination of the three-dimensional atomic structures of HCV NS5B or HCV NS5B in complex with substrates or substrate analogs or inhibitors |
| 09/11/2003 | US20030171569 A genetic engineered DNA molecule, probes, vectors, gene expression is inhibited by a growth hormone, for treating tumor; antitumor agents |
| 09/11/2003 | US20030171568 Diagnosing tumor or cancer in a mammal, and inflammatory diseases or disorders; inflammatory bowel disease, colon cancer; immunoassay, immunotherapy |
| 09/11/2003 | US20030171567 Recombinant allergen, fragments thereof, corresponding recombinant DNA molecules, vectors and hosts containing the DNA molecules, diagnostic and therapeutic uses of said allergens and fragments |
| 09/11/2003 | US20030171566 An isolated human nucleic acid encoding a nevoid basal cell carcinoma syndrome protein, antibodies, detecting tumor protein, therapeutic treatment of tumor, cancer; genetic engineering |
| 09/11/2003 | US20030171565 Purified and isolated protein zero related (PZR) and therapeutic and screening method using same |
| 09/11/2003 | US20030171563 Regulators of bacterial virulence factor expression |
| 09/11/2003 | US20030171562 Amino acid derivative antibiotics dorrigocin, and lactimidomycin, culturing Streptomyces amphibiosporus; computer readable medium with stored nucleotide sequences information, computers for data processing |
| 09/11/2003 | US20030171559 A colony-stimulating factor hybrid molecules, computer analyzing the three dimensional structure protein, crystallization of the protein |
| 09/11/2003 | US20030171558 Mucin immobilized chromatography |
| 09/11/2003 | US20030171556 Diagnosis and therapeutic treatment of Alzheimer's Disease; drug screening |
| 09/11/2003 | US20030171552 A single-chain T-cell receptor covalently linked to single-chain antibody; anticarcinogenic agents for treating cancer |
| 09/11/2003 | US20030171551 Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response |
| 09/11/2003 | US20030171550 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 09/11/2003 | US20030171549 Crystals and structures of YiiM proteins |
| 09/11/2003 | US20030171547 Adipocyte-specific protein homologs |
| 09/11/2003 | US20030171546 Chimeric immunoreceptor useful in treating human cancers |
| 09/11/2003 | US20030171542 Mammalian secretory peptide - 9 |
| 09/11/2003 | US20030171541 Selective binding agents, vectors, host cells, and methods for producing GPCR polypeptides; diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with GPCR polypeptides |
| 09/11/2003 | US20030171540 Novel protein zlmda33 |
| 09/11/2003 | US20030171538 Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus |
| 09/11/2003 | US20030171537 Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function |
| 09/11/2003 | US20030171536 Solid phase synthesis by the condensation of three partial fragments being carried out between the amino acid positions Glycine 108 and Arg 109 and amino acid positions Gly 120 and Cys 121; cyclization; deblocking; side-effects reduction |
| 09/11/2003 | US20030171535 Peptide derivatives |
| 09/11/2003 | US20030171334 Treatment of prostate cancer |
| 09/11/2003 | US20030171327 Determination and uses of the atomic structures of ribosomes and ribosomal subunits and their ligand complexes |
| 09/11/2003 | US20030171319 Human chemokine beta-10 mutant polypeptides |
| 09/11/2003 | US20030171318 Methods for inhibiting virus propagation and treating virus infection are provided which include administering to cells infected with viruses a compound capable of inhibiting viral budding from the cells. |
| 09/11/2003 | US20030171317 Methods and compositions for reducing bacterial tolerance to antibacterials, disinfectants and organic solvents |
| 09/11/2003 | US20030171313 Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to |
| 09/11/2003 | US20030171312 Dystrophin minigenes that retain the essential biological functions. The expression of the dystrophin minigenes may be controlled by a regulatory element along with a small polyadenylation signal. The entire gene expression cassettes |
| 09/11/2003 | US20030171298 Retroinverso polypeptides that mimic or inhibit thrombospondin |
| 09/11/2003 | US20030171297 A compound comprising tie amino acid sequence AMVSE, wherein said compound does not compromise the amino acid sequence EQEYVQTV The compound is useful as an anti-inflammatory agent. |
| 09/11/2003 | US20030171295 Drug screening assays, and diagnostic and therapeutic methods for the treatment of body weight disorders, such as obesity, anorexia and cachexia, utilizing the melanocortin 4-receptor (MC4-R) as the target for intervention |
| 09/11/2003 | US20030171293 Identification of an orphan G- protein coupled receptor MRGX2 (and variants thereof) as a receptor of neuropeptides such as but not limited to cortistatin, somatostatin, Bam 13-22, alpha -MSH, neuropeptide FF, dynorphin A and substance P, and the |
| 09/11/2003 | US20030171292 Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
| 09/11/2003 | US20030171289 Peptides blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
| 09/11/2003 | US20030171285 Chemically-modified human growth hormone conjugates |
| 09/11/2003 | US20030171284 The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves |
| 09/11/2003 | US20030171283 Inhibin compositions and methods of enhancing production performance |
| 09/11/2003 | US20030171282 Systemic delivery of parathyroid hormone to a mammalian host is accomplished by inhalation through the mouth of a dispersion of an N-terminal fragment of PTH. It has been found that such respiratory delivery of the PTH fragment |
| 09/11/2003 | US20030171280 Compositions and methods for modulation of immune responses |
| 09/11/2003 | US20030171278 Novel compounds which bind to the human erbB2 gene product (ErbB2, also known as HER2, or c-ErbB-2). In particular aspects, the invention provides for the treatment of disorders characterized by the overexpression of ErbB2 utilizing the |
| 09/11/2003 | US20030171277 Orally administered peptides to ameliorate atherosclerosis |
| 09/11/2003 | US20030171276 Capable of inhibiting the binding of hepatitis virus and a target cell, thereby preventing or treating chronic hepatitis; and a fusion interferon capable of still more improving a viral clearance ratio at the termination of |
| 09/11/2003 | US20030171275 Transporters and ion channels |
| 09/11/2003 | US20030171274 Antimicrobial proteins |
| 09/11/2003 | US20030171273 DNA of SEQ ID NO:1 is provided that encodes the transcription factor BP1, which is believed to be a repressor of the beta -globin gene. A host cell that is transformed with a vector that contains the DNA may be used to produce BP1. |
| 09/11/2003 | US20030171272 Cystatin superfamily includes inhibitors of cysteine proteinases, which function in a protective role with regard to various pathological actions of endogenous proteinases. Zcys7 is a new member of this superfamily. |
| 09/11/2003 | US20030171269 Novel epidermal growth factor protein and gene, and methods of use therefor |
| 09/11/2003 | US20030171268 polynucleotides which identify and encode HuLEAP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HuLEAP and a method for producing HuLEAP. |
| 09/11/2003 | US20030171267 Albumin fusion proteins |
| 09/11/2003 | US20030171266 Frameshift mutants of beta-amyloid precursor protein and ubiquitin-b and their use |
| 09/11/2003 | US20030171254 Purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, having a molecular mass of about 200 kDa, is provided. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful |
| 09/11/2003 | US20030171252 Nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for human |
| 09/11/2003 | US20030170917 4-Hydroxyalkylphenethamines, used as an intermediate, hapten, or immunogen in the production of antibodies specific for ecstasy drugs; binding the antibody to the analyte and detecting the adduct formed; immunoassay |
| 09/11/2003 | US20030170911 Non-oligomerizing fluorescent proteins |
| 09/11/2003 | US20030170896 Adeno-asociated virus (AAV) vectors that are capable of being transferred between cells; used to support comercially significant levels or rAAV particles without infectious helper virus or other harmful by-products |
| 09/11/2003 | US20030170895 Methods of making hypermutable cells using PMSR homologs |
| 09/11/2003 | US20030170885 Used for the transfer and expression of exogenous nucleotide sequences in a host cell or organism; gene therapy |
| 09/11/2003 | US20030170876 Methods for producing a polypeptide in a bacillus cell |
| 09/11/2003 | US20030170871 Alphavirus-based vectors for persistent infection |
| 09/11/2003 | US20030170870 For broad use in therapy and prevention including antisense agents and vaccines |
| 09/11/2003 | US20030170866 Novel cyclin-selective ubiquitin carrier polypeptides |
| 09/11/2003 | US20030170865 Novel polypeptide of protein p140 and DNAs encoding it |
| 09/11/2003 | US20030170864 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 09/11/2003 | US20030170862 Nuclear factor kappaB inducing factor |
| 09/11/2003 | US20030170853 Methods of gene therapy using nucleic acid sequences for ATP-binding cassette transporter |
| 09/11/2003 | US20030170852 Retina-specific detection of age-related macular degeneration; drug sceening |
| 09/11/2003 | US20030170851 Polypeptides comprising mutated kinase domain which is resistant to inhibition of its tyrosine kinase activity by N-(4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl)-4-( 4-methyl-piperazin-1-ylmethyl)-benzamide; drug screening |